V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies
about
Novel approaches to inhibit HIV entryMolecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structureTwo HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entryHigh-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virusReliable genotypic tropism tests for the major HIV-1 subtypesUse of mutual information arrays to predict coevolving sites in the full length HIV gp120 protein for subtypes B and C.Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kineticsDifferent tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection.A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsDistinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing.Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies.Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor ActivityDesign and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheetReplication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo.Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques.A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsImportance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domainHow HIV changes its tropism: evolution and adaptation?Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionality
P2860
Q27013957-5C964AE5-B96C-482B-8985-07402A1F922BQ27312441-F939CDA8-6755-473F-9C05-AFA2AAFFEF06Q28475912-FBAB7E27-D799-41D4-A5EA-2AF698B2DECFQ28482091-D4A36166-9E57-4CF4-BA9A-CD354C7FC8CFQ30372085-8C87C6A3-FF96-4A71-87DF-F4AEF51EC959Q30401569-16D366B5-DE07-4748-8C5C-8795C77D2DBAQ30603475-81A5B21E-2951-410F-A831-149025125EE8Q30654651-09B88FB7-6D42-431D-8073-33B583DB4482Q33429049-B2778093-5A7E-48CE-8A05-17B5E32A1980Q33558676-90F1A933-C3E5-4335-A8A3-BEC84560ECA2Q33725702-A82A1D33-E0D5-43C8-829C-262C6A5310FDQ33807529-A04F3345-069E-42F9-8AA3-6C0F5A566A32Q33990552-A9ED8807-1F06-4FCD-A10E-2066613FBFDAQ34055508-AD4021F4-FD7A-4F36-9785-3FF778D99873Q34299053-8B592384-9D81-42CD-9860-F1DEC2FFC3E1Q34463861-0372BEAC-B269-4BAC-90B0-2995135580C4Q34574397-DE0C09D2-9129-4156-A5BA-379554514482Q34606129-8841AC29-1FCA-4285-A58C-0BBC1779525EQ34610959-B950800A-E9ED-45DE-8F5B-2D1889C87630Q34611466-EC4D8CB7-C61A-4B0B-A971-81C2ED849189Q34742873-78DA8F6A-30FE-4415-80AB-EB00D092F2AFQ35102328-BC958A78-BA51-43AE-BB06-E87338F9C3F2Q35636394-9F4AE021-935B-44A3-AC4F-573FE6371B36Q35745453-2DFA4C40-9942-4632-8B4D-A8B444481A27Q36057328-32948352-CB4F-4C7F-A9D1-0B7156640C1DQ36098903-8CA2C03B-DC88-44D5-A36A-7BD4749506A2Q36424584-A30329D5-A24A-4F56-BF86-0C961E8633CAQ36559608-DE6F1DAB-123F-42A5-B23C-AEFC1DBCDF87Q36607127-0CC202A0-1F3A-4848-9D51-96F239D0982BQ36742476-F569ED91-729D-4896-89E7-B7014AC9E706Q36827168-1D6B2096-C2AF-41F4-9F79-42326394B1B1Q36827946-E4438882-58E2-4BA9-BAEA-463EF139436CQ36949880-362E0C41-D77E-462B-A5F0-5189CD18B63BQ37051645-50C22AC9-F02C-41EF-B72C-F301DA0CED4EQ37145319-EBBD4EE5-5FE1-4BD3-803E-C72812327573Q37146880-556975E9-B93D-464A-BD93-85EC2C57AC78Q37191794-EC65D21B-803D-4C1E-BD59-7D53ED9C63A1Q37192171-69418D8A-5D5B-4E28-8814-FD80806C4DA5Q37230002-7DFBB430-832C-485D-97AB-C1B59557301AQ37305864-1C79F839-9C99-467E-8369-267F63C31E5F
P2860
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies
@ast
V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies
@en
V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies
@nl
type
label
V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies
@ast
V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies
@en
V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies
@nl
prefLabel
V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies
@ast
V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies
@en
V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies
@nl
P2093
P2860
P3181
P1433
P1476
V3 loop truncations in HIV-1 e ...... ity to neutralizing antibodies
@en
P2093
Andrea P O Jordan
Beth Haggarty
Caroline Agrawal
Eric G Meissner
Fang-Hua Lee
George J Leslie
James A Hoxie
Josephine Romano
Katrina M Nolan
P2860
P3181
P356
10.1371/JOURNAL.PPAT.0030117
P407
P577
2007-08-24T00:00:00Z